Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | China | 28 Apr 2025 | |
Solid tumor | Preclinical | China | 28 Apr 2025 |